Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oleiferoside E is an oleanane-type triterpenoid saponin isolated from the roots of *Camellia oleifera* (commonly known as the oil-seed camellia or tea oil tree). Structurally, it consists of a pentacyclic oleanane aglycone with specific sugar moieties attached at the C-3 position. In preclinical *in vitro* pharmacological evaluations, oleiferoside E has demonstrated moderate cytotoxic activity against a variety of tumor cell lines, including A549 (lung cancer), B16 (melanoma), BEL-7402 (hepatocellular carcinoma), and MCF-7 (breast cancer). It is part of a series of related saponins (oleiferosides A-H) being researched for their potential as naturally derived antineoplastic agents. While its exact molecular targets are not yet fully defined, its activity is characteristic of the triterpenoid saponin class, which often interacts with cell membranes or induces apoptotic signaling in cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oleiferoside E.